# Digena

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digena

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.digena.com.cn
- Total disclosed funding: $16M
- Latest round: Series B (Mar 14, 2022)
- Investors on record: 5

## About

Based in Hangzhou, China and established in 2018, Digena operates as a biotechnology company that provides diagnostic equipment and diagnostic kit. The company has partnerships with Dian Diagnostics, Agena Bioscience, CITIC Securities, and other companies.

The company's products can be categorized into technology platforms, reagent products, and software products. Some of the main products within the technology platform category include nucleic acid mass spectrometer, and nanopore single molecule sequencer. Its nanopore single molecule sequencer can analyze DNA or RNA fragments in real time. It works by monitoring the current change when nucleic acid passes through nanopores, and decoding the current signal to determine the base sequence. Its reagent products can be applied in genetic diseases, pharmacogenomics, oncology, infectious diseases and health management.

## Funding rounds

- Series B, Mar 14, 2022, $16M — Crestvalue, Prosperico Ventures, Taikun Fund
- Series A, Oct 28, 2020 — CITIC Securities, TigerYeah Capital

## Investors

- CITIC Securities — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Crestvalue (https://capitalatlas.ai/funds/crestvalue) — Series B
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series B
- Taikun Fund — Series B